Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 16/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 16/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15377198 | 0.79 | SLC5A1 (0.46) | SLC5A1SLC5A2APOBEC3G | |
| SCHEMBL3176446 | 0.70 | PDE3B (0.38) | ALDH1A1LMNA | |
| SCHEMBL22197860 | 0.67 | MEN1 (0.62) | ALDH1A1APOBEC3GMEN1LMNAKMT2A | |
| SCHEMBL21218907 | 0.65 | MEN1 (0.51) | MEN1LMNAKMT2A | |
| SCHEMBL3773760 | 0.65 | MEN1 (0.51) | SLC5A1SLC5A2MEN1LMNAKMT2A | |
| SCHEMBL23453748 | 0.64 | MEN1 (0.57) | MEN1LMNAKMT2A | |
| SCHEMBL6419682 | 0.64 | NPC1 (0.39) | SLC5A1SLC5A2ALDH1A1APOBEC3G | |
| SCHEMBL13497016 | 0.64 | MEN1 (0.54) | SLC5A1SLC5A2MEN1LMNAKMT2A | |
| SCHEMBL23189233 | 0.63 | HCAR2 (0.52) | — | |
| SCHEMBL12803039 | 0.62 | ALDH1A1 (0.40) | ALDH1A1APOBEC3GMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| CN-102753184-A | Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases | SANOFI AVENTIS | 2012-10-24 | — | — | CN | disclosed |
| US-7820804-B2 | Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof | Sanofi-Aventia Deutschland GmbH (DE) | 2010-10-26 | — | — | US | disclosed |
| US-7820804-B2 | Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof | Sanofi-Aventia Deutschland GmbH (DE) | 2010-10-26 | — | — | US | disclosed |
| CN-100582116-C | Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds and their use | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-01-20 | — | — | CN | disclosed |
| EP-1758914-B1 | NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-21 | — | — | EP | disclosed |
| US-20070197623-A1 | NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197623-A1 | NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| CN-1964984-A | Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-05-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SLC5A1, SLC5A2, SOST | SLC5A1 1/4885SLC5A2 2/4885ALDH1A1 855/4885 |
| US-20070197623-A1 | NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | DPP4, UGGT1, SLC5A2 | SLC5A1 4/4885SLC5A2 3/4885ALDH1A1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.